Corbus Pharmaceuticals

$1.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.53%) Today
+$0.04 (+2.14%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell CRBP and other stocks, options, and ETFs commission-free!

About CRBP

Corbus Pharmaceuticals Holdings, Inc. Common Stock, also called Corbus Pharmaceuticals, is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA. The listed name for CRBP is Corbus Pharmaceuticals Holdings, Inc. Common Stock.

CEO
Yuval Cohen
Employees
141
Headquarters
Norwood, Massachusetts
Founded
2009
Market Cap
185.57M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
11.25M
High Today
$1.91
Low Today
$1.63
Open Price
$1.89
Volume
8.33M
52 Week High
$9.78
52 Week Low
$0.91

CRBP News

MarketWatchMar 5

Corbus Pharmaceuticals Holdings Inc. stock falls Friday, underperforms market

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP, -0.53% shed 0.53% to $1.87 Friday, on what proved to be an all-around great trading session for the stock m

CRBP Earnings

-$0.52
-$0.34
-$0.15
$0.03
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 19, Pre-Market

You May Also Like

MTSC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure